Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?

Biotech dominates in January as Intercept, Cell Therapeutics, and Neurocrine all surge after good drug-trial news.

Jan 27, 2014 at 12:15PM

One of the best things about being a long-term investor is that the law of gravity need not apply to good stocks -- what goes up doesn't necessarily have to come down. But some stocks can still fly too close to the sun, singing investors who bought in at too dear a price. When we're talking about momentum stocks, one investor's long-term winner could be another's warning sign, so it's important to separate the hype from the truth to find out just why a stock is soaring today, and whether it can keep rising tomorrow.

Today we'll look at three of the best-performing stocks on the market over the past month of trading. They might still be great candidates for your portfolio, but we won't know until we dig a little deeper.


Monthly Performance

Market Cap

P/E Ratio

Intercept Pharmaceuticals  (NASDAQ:ICPT)


$5.71 billion


Cell Therapeutics  (NASDAQ:CTIC)


$444 million


Neurocrine Biosciences (NASDAQ:NBIX)


$1.22 billion


Source: Finviz, YCharts , and Yahoo! Finance .

Intercept Pharmaceuticals
Few public companies in any industry -- even in the incredibly volatile biotech space -- have ever enjoyed the rocket ride Intercept went on earlier this month -- in just one day, shares gained more than 300% after Intercept publicized a positive recommendation for its obeticholic acid, or OCA, treatment for nonalcoholic steatohepatitis, or NASH. The treatment showed statistically significant improvements in the condition of many patients in Intercept's phase 2b trial. Considering the sheer size of the affected population -- up to 12% of Americans have NASH -- many investors felt this report marked the beginning of a major blockbuster drug, one that has no visible competition. The megapop continued for a second day and Intercept's shares topped out at a two-day gain of more than 500%.

ICPT Total Return Price Chart

ICPT Total Return Price data by YCharts.

Since topping out at about $445, Intercept's shares sank back to a slightly more reasonable price of about $300 (as of this writing), and the 500% gain became a 350% gain. Still, investors who have held on since Intercept's late-2012 IPO have nothing to complain about, as they have a 15-bagger on their hands after little more than one year of trading.

However, Intercept is still small enough and tightly focused enough that its share-price moves in the near future will likely be driven entirely by rumors, press releases, and short-selling raids. That adds up to extreme volatility, and months or years can be expected to pass before the Food and Drug Administration clears OCA -- if it is cleared at all. Iron-willed investors may be able to clamp down and hold on for the ride, but those with a weaker understanding of biotech investing, or a weaker constitution when it comes to volatility, are probably better off on the sidelines.

Cell Theraputics
Unlike its larger biotech peer at the top of this week's list, Cell Therapeutics hasn't been propelled by one single massive pop. As is often the case, the company has been rising throughout January as a result of several pieces of good news. Cell Therapeutics' Pixuvri, a treatment for non-Hodgkin lymphoma, was approved by Britain's National Institute for Health and Care Excellence as a cost-effective treatment option. On the other side of the pond, Cell Therapeutics' leukemia drug Tosedostat was released from a partial FDA clinical hold.

Later in the month, Cell Therapeutics provided guidance for the rest of 2014 that indicated further progress on trials for pacritinib and Opaxio, which gave shares another double-digit boost. The company also managed to regain the full rights to both Pixuvri and Opaxio from former partner Novartis (NYSE:NVS). All told, the positive momentum propelled Cell Therapeutics to a double for the month of January:

CTIC Total Return Price Chart

CTIC Total Return Price data by YCharts.

However, Fool contributor and biotech specialist Sean Williams pointed out that this recent good news is simply one bump on a steady downward slide that has shredded virtually all shareholder value over the past decade. Indeed, when examined on a 10-year timeline, we find that Cell Therapeutics' recent pop is completely invisible to the naked eye:

CTIC Total Return Price Chart

CTIC Total Return Price data by YCharts.

It's only when we zoom in to the past year that Cell Therapeutics again looks like a good investment. Williams, though, also notes that the company didn't actually wrest back the rights to two of its biggest drugs -- Novartis simply didn't want to license the drugs in the first place. The company has only one drug approved, and even then only in Europe. On the other hand, analysts at Roth Capital recently pegged their price target for Cell Therapeutics shares at $7, up from $6, and at current share prices this represents a hefty 75% upside. History isn't on Cell Therapeutics' side, so it may be better to sit on the sidelines here.

Neurocrine Biosciences
The biotech clean sweep is complete for the month of January with Neurocrine Biosciences, another developmental-stage company with one huge day propelling it higher. Neurocrine has taken investors on quite the violent ride over the last few months, and all over the same drug -- its tardive dyskinesia drug NBI-98854 produced disappointing results last September, but after reworking the study Neurocrine managed to produce some success. Investors then flocked to the stock, which nearly doubled in a single day:

NBIX Total Return Price Chart

NBIX Total Return Price data by YCharts.

Neurocrine's megapop has proven to be more sustainable than top performer Intercept's leap, as it remains roughly in line with its post-pop closing price several weeks later. However, while both Neurocrine and Intercept have developed promising new drugs with no apparent competition, investor enthusiasm over Intercept's positive progress was so extreme that it makes Neurocrine look like a bargain by comparison. It might be a long way from FDA approval, but Sean Williams thinks that NBI-98854 has a better chance of surprising investors to the upside with its long-term sales figures. This month's megapops are not for the faint of heart, but if you still want to rush in after the big gain, Neurocrine might be your best bet.

Still looking for a great long-term biotech investment? Look here
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information